CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice

American Journal of Pathology

Volumn 162, Issue 2, 2003, Pages 691-702

  Erdman, Susan E ^a   Poutahidis, Theofilos ^a   Tomczak, Michal ^b   Rogers, Arlin B ^a   Cormier, Kathleen ^a   Plank, Benjamin ^b   Horwitz, Bruce H ^b,c   Fox, James G ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; RAG2 PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RISK; COLON CANCER; COLON CARCINOGENESIS; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HELICOBACTER HEPATICUS; HELICOBACTER PYLORI; IMMUNOREGULATION; INFLAMMATION; INTESTINE EPITHELIUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 0037331279     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63863-1     Document Type: Article

References (65)

1. Riddell RH, Goldman H, Ransohoff DF, Appleman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC, Yardley JH: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931-968
2. Crawford JM (Ed): The Gastrointestinal Tract. Philadelphia, WB Saunders, 1999
3. Fiocchi C: Inflammatory bowel disease: etiology and prevention. Gastroenterology 1998, 115:182-205
4. MacDonald TT, Montelone G, Pender SLF: Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000, 51:2-9
5. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991, 325:1127-1131
6. Ley C, Parsonnet J (Eds): Gastric Adenocarcinoma. Totowa. Humana Press, Inc., 2000
7. El-Omar EM, Malfertheiner P: Helicobacter pylori and gastric cancer. Curr Opin Gastroenterol 2001, 17(Suppl 1):S24-S27
8. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111
9. Pardoll D: T cells and tumors. Nature 2001, 411:1010-1012
10. Powrie F: T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995, 3:171-174
11. Cahill RJ, Foltz CJ, Fox JG, Dangler CA, Powrie F, Schauer DB: Inflammatory bowel disease: an immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun 1997, 65:3126-3131
12. Kuliberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, Jankovic D, Sher S: Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 1998, 66:5157-5166
13. Kuliberg MC, Rothfucs AG, Jankovic D, Caspar P, Wynn TA, Gorelick PL, Cheever AW, Sher A: Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun 2001, 69:4232-4241
14. Iqbal N, Oliver JR, Wagner FH, Lazenby AS, Elson CO, Weaver CT: T helper 1 and T helper 2 cells are pathogenic in an antigen specific model of colitis. J Exp Med 2002, 195:71-84
15. Kado S, Uchida K, Funabashi H, Iwata S, Nagata Y, Ando M, Onoue M, Matsuoka Y, Ohwaki M, Morotomi M: Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 2001, 61:2395-2398
16. Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB: Bacterial infection promotes colon tumorigenesis in Apc min/+ mice. J Infect Dis 2001, 184:227-230
17. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM: Rag-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J chain rearrangement. Cell 1992, 68:855-867
18. Groux H, Powrie F: Regulatory T cells and inflammatory bowel disease. Immunol Today 1999, 20:442-445
19. Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA, Stepankova R, Tiaskalova H, Powrie F: Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001, 182:190-200
20. Engle SJ, Hoying JB, Bolvin GP, Ormsby I, Gartside PS, Doetschman T: Transforming growth factor beta-1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999, 59:3379-3386
21. von Freeden-Jeffry U, Davidson N, Wiler R, Fort M, Burdach S, Murray R: IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis. J Immunol 1998, 161:5673-5680
22. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994, 179:589-600
23. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-741
24. Papiernik M: Natural CD4+ CD25+ regulatory T cells: their role in control of superantigen responses. Immunol Rev 2001, 182:180-189
25. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001, 31:1122-1131
26. Stephens LA, Mottet C, Mason D, Powrie F: Human CD4+CD25+ thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001, 31:1247-1254
27. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302
28. Maloy K, Powrie F: Regulatory cells in the control of immune pathology. Nature Immunol 2001, 2:816-822
29. Fox JG, Sheppard BJ, Dangler CA, Whary MT, Ihrig M, Wang TC: Germline p53 mutation inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through downregulation of TH1 proinflammatory responses. Cancer Res 2002, 62:696-702
30. Fox JG, Dewhirst FE, Tully JG, Paster BJ, Yan L, Taylor NS, Collins MJ, Gorerick PL, Ward JM: Helicobacter hepaticus species. nov. a microaerophilic bacterium isolated form livers and intestinal mucosal scrapings from mice. J Clin Microbiol 1994, 32:1238-1245
31. Fox JG, Yan L, Shames B, Campbell J, Murphy JC: Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect Immun 1996, 64:3673-3681
32. Shames B, Fox JG, Dewhirst F, Yan L, Shen Z, Taylor NS: Identification of widespread Helicobacter hepaticus infection in feces in commercial mouse colonies by culture and PCR assay. J Clin Microbiol 1995, 33:2968-2972
33. Fox J, Dewhirst FE, Shen Z, Feng Y, Taylor NS, Paster BJ, Ericson RL, Lau CN, Correa P, Araya JC, Roa I: Hepatic Helicobacter species identified in bile and gallbladder from Chileans with chronic cholecystitis. Gastroenterology 1998, 114:755-763
34. Horwitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D: Failure of Lymphopoiesis after adoptive transfer of NF-kB deficient fetal liver cells. Immunity 1997, 6:765-772
35. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D: Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996, 98:1010-1020
36. Schempler RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Habashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner G, Price AB, Ribio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Vamabe H: The Vienna Classification of gastrointestinal epithelial neoplasia. Gut 2000, 47:251-255
37. Hamilton SR, Aaltonen LA: Pathology and genetics of tumors of the digestive system. World Health Organization Classification of Tumors. Lyon, IARC Press, 2000
38. Schempler RJ, Kato Y, Stolte M: Diagnostic criteria for gastrointestinal carcinomas in Japan and Western countries: proposal for a new classification of gastrointestinal epithelial neoplasia. Gastroenterol Hepatol 2000, Oct 15:G49-G57
39. Dewhirst FE, Chien CC, Paster BJ, Ericson RL, Orcutt RP, Schauer DB, Fox JG: Phylogeny of the defined murine microbiota: altered Schaedler flora. App. Environ Microbiol 1999, 65:3287-3292
40. Ge Z, White DA, Whary MT, Fox JG: Fluorogenic PCR-based quantitative detection of a murine pathogen, Helicobacter hepaticus. J Clin Microbiol 2001, 39:2598-2602
41. Whary MT, Cline J, King A, Ge Z, Shen Z, Sheppard B, Fox JG: Long-term colonization levels of Helicobacter hepaticus in the cecum of hepatitis-prone A/JCr mice are significantly lower than those in hepatitis-resistant C57BL/6 mice. Comp Med 2001, 51:413-417
42. Ward JM, Anver MR, Haines DC, Melhorn JM, Gorelick P, Yan L, Fox JG: Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. Lab Anim Sci 1996, 46:15-20
43. Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, Schauer DB: Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter 1998, 3:69-78
44. Erdman SE, Fox JG, Dangler CA, Feldman D, Horwitz BH: Cutting edge: typhlocolitis in NF-kB-deficient mice. J Immunol 2001, 166:1443-1447
45. Fox JG, Li X, Yan L, Cahill RJ, Hurley R, Lewis R, Murphy JC: Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: a model of Helicobacter-induced carcinogenesis. Infect Immun 1996, 64:1548-1558
46. Hailey JR, Haseman JK, Bucher JR, Radovsky AE, Malarkey DE, Miller RT, Nyska A, Maronpot RP: Impact of Helicobacter hepaticus infection in B6C3F1 mice from twelve National Toxicology Program two-year carcinogenesis studies. Toxicol Pathol 1998, 26:602-611
47. Ihrig M, Schrenzel M, Fox JG: Differential susceptibility of hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with Helicobacter hepaticus. Am J Pathol 1999, 155:571-582
48. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process. First American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992, 52:6735-6740
49. Wang T, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GH, Fox JG: Synergistic interaction between hypergastrinemia and helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000, 118:36-47
50. Noffsinger AE, Miller MA, Cusi MV, Fenoglio-Preiser CM: The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer 1996, 78:2307-2312
51. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A: Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study in histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000, 21:757-768
52. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, Rogy MA: Interleukin-10-deficient mice and inflammatory bowel disease associated colon cancer. Carcinogenesis 2001, 22:665-671
53. Rennick DM, Fort MM: Lessons from genetically engineered animal models XII. IL10-deficient mice and intestinal inflammation. Am J Physiol 2000, 278:G829-G833
54. Kundu N, Fulton MA: Interleukin 10 inhibits tumor metastasis, down-regulates MHC class 1, and enhances NK lysis. Cell Immunol 1997, 180:55-61
55. Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, Westrich G, Viney JL, Maggio-Price L: Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol 2001, 281: G764-G778
56. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4+ T cells in antitumor immune response. J Exp Med 1998, 188:2357-2368
57. Powrie F, Leach W, Mauze S, Menon L, Caddle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562
58. Claesson MH, Bregenholt S, Bonhagen K, Stefan T, Moller P, Grusby MJ, Leithauser F, Nissen MH, Reimann J: Colitis-inducing potency of CD4+ T cells in immunodeficient adoptive hosts depends upon their state of activation, IL12 responsiveness, and CD45RB phenotype. J Immunol 1999, 162:3702-3710
59. Kullberg MC, Jankovic D, Gorelick PL, Caspar P, Letterio JJ, Cheever AW, Sher A: Bacteria-triggered CD4+ T regulatory cells suppress Helicobacter hepaticus-induced colitis. J Exp Med 2002, 196:1-13
60. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandiera A: Regulatory CD4+ T cells control the size of the peripheral activated/memory CD4+ T cell compartment. J Immunol 2000, 164:3537-3580
61. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190:995-1004
62. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765
63. Aste-Amezaga M, Ma X, Sartori A, Trinchieri G: Molecular mechanisms of the induction of IL12 and its inhibition by IL10. J Immunol 1998, 160:5936-5944
64. Blumberg RS, Saubermann LJ, Strober W: Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999, 11:648-656
65. Segal BM, Glass DD, Shevach EM: Cutting edge: IL10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002, 168:1-4